Novonix (NVX) Q3 2026 TU earnings summary

Executive summary

• Riverside qualification advanced: initial C-sample met most specifications, with remaining parameters under active development; commercial sales remain contingent on customer approval and operational conditions.

• Quarter-end cash was US$33.652 million; operating cash outflow was US$9.765 million, and a US$7 million Yorkville debenture repayment was made in September, with another US$7 million paid in October.

Financial highlights

• Net cash used in operating activities was US$9.765 million in Q3 and US$32.820 million for 9M; customer receipts were US$582,000 and US$2.703 million, respectively.

• Q3 investing cash outflow was US$9.169 million, including US$8.360 million for property, plant and equipment; 9M capex was US$17.390 million.

• Q3 financing cash outflow was US$6.829 million; 9M financing cash inflow was US$5.434 million, including US$15.190 million in equity proceeds and US$7.805 million in borrowing repayments.

• Cash and cash equivalents declined from US$59.535 million at the prior quarter end to US$33.652 million at 30 September 2026.

Outlook and guidance

• Previously communicated expectation for mass-production sales in H2 2027 remains subject to successful qualification and other operational and commercial conditions.

• Near-term priorities include customer qualification, manufacturing readiness, quality systems, operating-cost discipline, and strategic financing to support commercial growth.

• Riverside qualification requires further customer testing and approval; ISO 9001 certification supports readiness but does not constitute product qualification.